Arthneeti
All Q2 FY27 results →
CB

Concord Biotech Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Concord Biotech Q2 Results 2026 (FY27): Revenue ₹309.1 Cr, PAT ₹69.6 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹1,375
Market cap₹14.4K Cr
P/E50.6
Updated27 Oct 2026
Read3 min read

Concord Biotech Ltd Q2 FY27 key numbers

Revenue
API Revenue Q2FY27: ₹250.2 Cr (30% YoY growth).

As stated in Concord Biotech Ltd's Q2 FY27 investor presentation · published 27 Oct 2026. Reported figures, not investment advice.

Based on Concord Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2FY27 Revenue from Operations: ₹309.1 Cr (25.1% YoY growth vs. Q2FY27 Results vs Q2FY26: - EBITDA: ₹104.4 Cr, up 18.0% YoY (from ₹88.5 Cr) - EBITDA Margin: 33.8%, down 200 bps YoY (from 35.8%) - PAT: ₹69.6 Cr, up 10.3% YoY (from ₹63.1 Cr) - PAT Margin: 22.5%, down 300 bps YoY (from 25.5%) - Operating Profit (EBIT): ₹96.2 Cr, up 15.3% YoY (from ₹83.4 Cr) - Margin Outlook: - EBITDA margins (excluding impact of Injectable Facility & Stellon Biotech expenses) were 37.1% for Q2FY27.

From Concord Biotech Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.

Revenue & Sales Performance

  • Q2FY27 Revenue from Operations: ₹309.1 Cr (25.1% YoY growth vs. ₹247.1 Cr in Q2FY26)
  • H1FY27 Revenue: ₹566.6 Cr (25.6% YoY growth vs. ₹451.1 Cr in H1FY26)
  • API Revenue Q2FY27: ₹250.2 Cr (30% YoY growth)
  • Formulation Revenue Q2FY27: ₹58.9 Cr (6% YoY growth)
  • Domestic Revenue Q2FY27: ₹130.4 Cr (+8% YoY)
  • Exports Revenue Q2FY27: ₹178.7 Cr (+42% YoY)

2 more points from Concord Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Unit III API Facility, Limbasi:
  • Site area: 5,96,309 sq.m.
  • Installed fermentation capacity: 800 m³
  • Commissioned in FY2021
  • Unit IV Injectable Facility, Valthera:
  • Site area: 36,441 sq.m.
  • Injectable capacity: 13 million liquid vials, 12 million dry powder filling, 2,200 kg sterile lyophilized
  • Expected capacity by FY2025
  • Capex and Utilization:
  • Expansion Initiatives:
  • Dermatology division launch (Inspira) introduced in Q2 FY27, expanding formulations portfolio

2 more points from Concord Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Concord Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Concord Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Concord Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Ltd Q2 FY27 results?

Q2FY27 Revenue from Operations: ₹309.1 Cr (25.1% YoY growth vs. Q2FY27 Results vs Q2FY26: - EBITDA: ₹104.4 Cr, up 18.0% YoY (from ₹88.5 Cr) - EBITDA Margin: 33.8%, down 200 bps YoY (from 35.8%) - PAT: ₹69.6 Cr, up 10.3% YoY (from ₹63.1 Cr) - PAT Margin: 22.5%, down 300 bps YoY (from 25.5%) - Operating Profit (EBIT): ₹96.2 Cr, up 15.3% YoY (from ₹83.4 Cr) - Margin Outlook: - EBITDA margins (excluding impact of Injectable Facility & Stellon Biotech expenses) were 37.1% for Q2FY27.

What is Concord Biotech Ltd share price analysis?

Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 50.6 with a market cap of ₹14,388 Cr. Investors should review the full earnings analysis for detailed insights.

Is Concord Biotech Ltd planning capital expenditure?

Unit III API Facility, Limbasi: - Site area: 5,96,309 sq.m.

Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.